PT  - JOURNAL ARTICLE
AU  - Andreas Heinzel
AU  - Eva Schretzenmeier
AU  - Florina Regele
AU  - Karin Hu
AU  - Lukas Raab
AU  - Michael Eder
AU  - Christof Aigner
AU  - Rhea Jabbour
AU  - Constantin Aschauer
AU  - Ana-Luisa Stefanski
AU  - Thomas Dörner
AU  - Klemens Budde
AU  - Roman Reindl-Schwaighofer
AU  - Rainer Oberbauer
TI  - Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
AID  - 10.1101/2022.02.22.22270838
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.22.22270838
4099  - http://medrxiv.org/content/early/2022/02/24/2022.02.22.22270838.short
4100  - http://medrxiv.org/content/early/2022/02/24/2022.02.22.22270838.full
AB  - Importance Response to SARS-CoV-2 vaccines in kidney transplant recipients (KTR) is severely reduced. Heterologous 3rd vaccination combining mRNA and vector vaccines did not increase seroconversion at four weeks after vaccination but evolution of antibody levels beyond the first month remain unknown.Objective To assess changes in antibody response following a 3rd vaccination with mRNA or vector vaccine in KTR from month one to month three after vaccination.Design, Setting and Participants Three-month follow-up (pre-specified secondary endpoint) of a single-center, single-blinded, 1:1 randomized, controlled trial on 3rd vaccination against SARS-CoV-2 in 201 KTR who did not develop SARS-CoV-2 spike protein antibodies following two doses of an mRNA vaccine.Intervention(s) mRNA (BNT162b2 or mRNA-1273) or vector (Ad26COVS1) as 3rd SARS-CoV-2 vaccineMain Outcomes and Measures Main outcome was seroconversion at the second follow-up between 60-120 days after the 3rd vaccination. Subsequently, higher cut-off levels associated with neutralizing capacity and protective immunity were applied (i.e. >15, >100, >141 and >264 BAU/mL). In addition, trajectories of antibody levels from month one to month three were analyzed. Finally, SARS-CoV-2 specific CD4 and CD8 T-cells at four weeks were compared among the 18 top responders in both groups.Results A total of 169 patients were available for the three-month follow-up. Overall, seroconversion at three months was similar between both groups (45% versus 50% for mRNA and vector group, respectively; OR=1.24, 95%CI=[0.65, 2.37], p=0.539). However, when applying higher cut-off levels, a significantly larger number of individual in the vector group reached antibody levels > 141 and > 264 BAU/mL at the three-month follow-up (141 BAU/mL: 4% vs. 15% OR=4.96, 95%CI=[1.29, 28.21], p=0.009 and 264 BAU/mL: 1% vs. 10% OR=8.75, 95%CI=[1.13, 396.17], p=0.018 for mRNA vs. vector vaccine group, respectively). In line, antibody levels in seroconverted patients further increased from month one to month three in the vector group while remaining unchanged in the mRNA group (median increase: mRNA= 1.35 U/mL and vector = 27.6 U/mL, p = 0.004). Of particular note, there was no difference in the CD4 and CD8 T-cell response between the mRNA and vector vaccine group at month one.Conclusions and Relevance Despite a similar overall seroconversion rate at three months following 3rd vaccination in KTR, a heterologous 3rd booster vaccination with Ad26COVS1 resulted in significantly higher antibody levels in responders.Trial Registration EurdraCT: 2021-002927-39Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEurdraCT: 2021-002927-39Funding StatementMedical-Scientific Fund of the Mayor of Vienna, the Christine Vranitzky-Stiftung research grant 2020 (both to Roman Reindl-Schwaighofer) and the Transplantation Research Platform's Start-Up Grant 2020 (to Andreas Heinzel)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Medical University of Vienna gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors